Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?

50Citations
Citations of this article
149Readers
Mendeley users who have this article in their library.

Abstract

With over 15 FDA approved drugs on the market and numerous ongoing clinical trials, RNA therapeutics, such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), have shown great potential to treat human disease. Their mechanism of action is based entirely on the sequence of validated disease-causing genes without the prerequisite knowledge of protein structure, activity or cellular location. In contrast to small molecule therapeutics that passively diffuse across the cell membrane’s lipid bilayer, RNA therapeutics are too large, too charged, and/or too hydrophilic to passively diffuse across the cellular membrane and instead are taken up into cells by endocytosis. However, endosomes are also composed of a lipid bilayer barrier that results in endosomal capture and retention of 99% of RNA therapeutics with 1% or less entering the cytoplasm. Although this very low level of endosomal escape has proven sufficient for liver and some CNS disorders, it is insufficient for the vast majority of extra-hepatic diseases. Unfortunately, there are currently no acceptable solutions to the endosomal escape problem. Consequently, before RNA therapeutics can be used to treat widespread human disease, the rate-limiting delivery problem of endosomal escape must be solved in a nontoxic manner.

References Powered by Scopus

Lead- and drug-like compounds: The rule-of-five revolution

4425Citations
N/AReaders
Get full text

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

2029Citations
N/AReaders
Get full text

Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis

1495Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Dowdy, S. F. (2023). Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem? RNA, 29(4), 396–401. https://doi.org/10.1261/rna.079507.122

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 34

58%

Researcher 18

31%

Professor / Associate Prof. 5

8%

Lecturer / Post doc 2

3%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 21

41%

Pharmacology, Toxicology and Pharmaceut... 13

25%

Chemistry 10

20%

Agricultural and Biological Sciences 7

14%

Save time finding and organizing research with Mendeley

Sign up for free